Options
Nitish R Mahapatra
Loading...
Preferred name
Nitish R Mahapatra
Official Name
Nitish R Mahapatra
Alternative Name
Mahapatra, N. R.
Mahapatra, Nitish R.
Main Affiliation
ORCID
Scopus Author ID
Google Scholar ID
48 results
Now showing 1 - 10 of 48
- PublicationChromogranin A: A novel susceptibility gene for essential hypertension(01-03-2010)
;Sahu, Bhavani S. ;Sonawane, Parshuram J.Chromogranin A (CHGA) is ubiquitously expressed in secretory cells of the endocrine, neuroendocrine, and neuronal tissues. Although this protein has long been known as a marker for neuroendocrine tumors, its role in cardiovascular disease states including essential hypertension (EH) has only recently been recognized. It acts as a prohormone giving rise to bioactive peptides such as vasostatin-I (human CHGA1-76) and catestatin (human CHGA352-372) that exhibit several cardiovascular regulatory functions. CHGA is over-expressed but catestatin is diminished in EH. Moreover, genetic variants in the promoter, catestatin, and 3'-untranslated regions of the human CHGA gene alter autonomic activity and blood pressure. Consistent with these findings, targeted ablation of this gene causes severe arterial hypertension and ventricular hypertrophy in mice. Transgenic expression of the human CHGA gene or exogenous administration of catestatin restores blood pressure in these mice. Thus, the accumulated evidence establishes CHGA as a novel susceptibility gene for EH. - PublicationIntegrated computational and experimental analysis of the neuroendocrine transcriptome in genetic hypertension identifies novel control points for the cardiometabolic syndrome(01-08-2012)
;Friese, Ryan S. ;Ye, Chun ;Nievergelt, Caroline M. ;Schork, Andrew J.; ;Rao, Fangwen ;Napolitan, Philip S. ;Waalen, Jill ;Ehret, Georg B. ;Munroe, Patricia B. ;Schmid-Schönbein, Geert W. ;Eskin, EleazarO'Connor, Daniel T.Background: Essential hypertension, a common complex disease, displays substantial genetic influence. Contemporary methods to dissect the genetic basis of complex diseases such as the genomewide association study are powerful, yet a large gap exists betweens the fraction of population trait variance explained by such associations and total disease heritability. Methods and Results: We developed a novel, integrative method (combining animal models, transcriptomics, bioinformatics, molecular biology, and trait-extreme phenotypes) to identify candidate genes for essential hypertension and the metabolic syndrome. We frst undertook transcriptome profiling on adrenal glands from blood pressure extreme mouse strains: the hypertensive BPH (blood pressure high) and hypotensive BPL (blood pressure low). Microarray data clustering revealed a striking pattern of global underexpression of intermediary metabolism transcripts in BPH. The MITRA algorithm identified a conserved motif in the transcriptional regulatory regions of the underexpressed metabolic genes, and we then hypothesized that regulation through this motif contributed to the global underexpression. Luciferase reporter assays demonstrated transcriptional activity of the motif through transcription factors HOXA3, SRY, and YY1. We finally hypothesized that genetic variation at HOXA3, SRY, and YY1 might predict blood pressure and other metabolic syndrome traits in humans. Tagging variants for each locus were associated with blood pressure in a human population blood pressure extreme sample with the most extensive associations for YY1 tagging single nucleotide polymorphism rs11625658 on systolic blood pressure, diastolic blood pressure, body mass index, and fasting glucose. Meta-analysis extended the YY1 results into 2 additional large population samples with significant effects preserved on diastolic blood pressure, body mass index, and fasting glucose. Conclusions: The results outline an innovative, systematic approach to the genetic pathogenesis of complex cardiovascular disease traits and point to transcription factor YY1 as a potential candidate gene involved in essential hypertension and the cardiometabolic syndrome. © 2012 American Heart Association, Inc. - PublicationCatestatin: A master regulator of cardiovascular functions(01-01-2018)
;Mahata, Sushil K. ;Kiranmayi, MalapakaBackground: Cardiovascular disease (CVD), the most common cause of death globally, accounts for ~30% of all deaths worldwide. Hypertension is a common contributor to morbidity and mortality from CVD. Methods and Results: The plasma concentration of chromogranin A (CgA) is elevated in patients with CVD as well as patients with established human essential hypertension and heart failure (HF). In contrast, the plasma level of the CgA-derived peptide catestatin (CST) is diminished in human essential hypertension. Low conversion of CgA-to-CST has been associated with increased mortality in patients hospitalized with acute HF. Consistent with human findings, the lack of CST in CgA knockout (Chga-KO) mice eventuates in the development of hypertension and supplementation of CST to Chga-KO mice restores blood pressure, implicating CST as a key player in regulating hypertension. In the peripheral system, CST decreases blood pressure by stimulating histamine release, inhibiting catecholamine secretion, or causing vasodilation. Centrally, CST improves baroreflex sensitivity (BRS) and heart rate variability (HRV) by exciting GABAergic neurons in the caudal ventrolateral medulla (CVLM) and pyramidal neurons of the central amygdala; CST also decreases BRS by exciting glutamatergic rostral ventrolateral medulla (RVLM) neurons. In addition, CST provides cardioprotection by inhibiting inotropy and lusitropy; activating mitochondrial KATP channels, and stimulating reperfusion injury salvage kinase (RISK) and survivor activating factor enhancement (SAFE) pathways and consequent inhibition of mitochondrial permeability transition pore (mPTP). CST modulates cardiomyocyte Ca2+ levels by direct inhibition of Ca2+/calmodulin-dependent protein kinase IIδ (CaMKIIδ) activity and consequent reduction in phosphorylation of phospholamban and ryanodine receptor 2, thereby providing support for a direct functional role of CST in the failing myocardium. Conclusion: These multitude of effects establish CST as a master regulator of cardiovascular functions. - PublicationMolecular interactions of the physiological anti-hypertensive peptide catestatin with the neuronal nicotinic acetylcholine receptor(01-06-2012)
;Sahu, Bhavani S. ;Mohan, Jagan ;Sahu, Giriraj ;Singh, Pradeep K. ;Sonawane, Parshuram J. ;Sasi, Binu K. ;Allu, Prasanna K.R. ;Maji, Samir K.; ; - PublicationRenalase: a novel regulator of cardiometabolic and renal diseases(01-10-2022)
;Vijayakumar, AnupamaRenalase is a ~38 kDa flavin-adenine dinucleotide (FAD) domain-containing protein that can function as a cytokine and an anomerase. It is emerging as a novel regulator of cardiometabolic diseases. Expressed mainly in the kidneys, renalase has been reported to have a hypotensive effect and may control blood pressure through regulation of sympathetic tone. Furthermore, genetic variations in the renalase gene, such as a functional missense polymorphism (Glu37Asp), have implications in the cardiovascular and renal systems and can potentially increase the risk of cardiometabolic disorders. Research on the physiological functions and biochemical actions of renalase over the years has indicated a role for renalase as one of the key proteins involved in various disease states, such as diabetes, impaired lipid metabolism, and cancer. Recent studies have identified three transcription factors (viz., Sp1, STAT3, and ZBP89) as key positive regulators in modulating the expression of the human renalase gene. Moreover, renalase is under the post-transcriptional regulation of two microRNAs (viz., miR-29b, and miR-146a), which downregulate renalase expression. While renalase supplementation may be useful for treating hypertension, inhibition of renalase signaling may be beneficial to patients with cancerous tumors. However, more incisive investigations are required to unravel the potential therapeutic applications of renalase. Based on the literature pertaining to the function and physiology of renalase, this review attempts to consolidate and comprehend the role of renalase in regulating cardiometabolic and renal disorders. - PublicationBio-effective disease control and plant growth promotion in lentil by two pesticide degrading strains of Bacillus sp.(01-12-2018)
;Roy, Tina ;Bandopadhyay, Anuradha ;Sonawane, Parshuram J. ;Majumdar, Sukanta; ;Alam, SharifulDas, NirmalenduAntagonistic bacteria are common soil inhabitants with potential to control several soil-borne diseases of various crops. In this study, two methomyl degrading Bacillus sp. were screened for their antagonistic potential against soil borne pathogen identified as Alternaria sp. which causes leaf spot and blight disease in lentil. Both the strains produced non-volatile and volatile organic compounds, extracellular enzymes, siderophore, indole acetic acid and solubilized phosphate which ascribed to the mechanism of bio-control and plant growth promotion. These bacterial strains produced indole acetic acid, chitinase and solubilized phosphate even in presence of pesticides (namely methomyl, carbendazim and imidacloprid). The production of chitinase increased by 51–140% in presence of different tested pesticides by the bacterial strains. However, phosphate solublization was only increased up to 79% in B. cereus and 87% in B. safensis in presence of methomyl. Both strains promoted plant growth and suppressed leaf spot and the incidence of blight in lentil plants under controlled conditions in green house. Application of B. cereus and B. safensis isolates to sterile rhizospheric soil increased the dry weight of plants by 40.8% and 43.2%, respectively as compared to control. In similar set of experiments the disease incidence was reduced by 67.7–81.6% in B. cereus and 57.2–78.8% in B. safensis in sterile condition and by 51.4–76.5% and 48.6–63.4%, respectively in non-sterile condition. The present investigation shows both B. cereus and B. safensis as potential plant growth promoting rhizobacteria that can be exploited as efficient bio-control organisms against soil borne plant pathogens as well as can be applied in plant growth enhancement even in pesticide infested soil. - PublicationChromogranin A and its derived peptides: potential regulators of cholesterol homeostasis(01-09-2023)
;Iyer, Dhanya R. ;Venkatraman, Janani ;Tanguy, Emeline ;Vitale, NicolasChromogranin A (CHGA), a member of the granin family of proteins, has been an attractive therapeutic target and candidate biomarker for several cardiovascular, neurological, and inflammatory disorders. The prominence of CHGA stems from the pleiotropic roles of several bioactive peptides (e.g., catestatin, pancreastatin, vasostatins) generated by its proteolytic cleavage and by their wide anatomical distribution. These peptides are emerging as novel modulators of cardiometabolic diseases that are often linked to high blood cholesterol levels. However, their impact on cholesterol homeostasis is poorly understood. The dynamic nature of cholesterol and its multitudinous roles in almost every aspect of normal body function makes it an integral component of metabolic physiology. A tightly regulated coordination of cholesterol homeostasis is imperative for proper functioning of cellular and metabolic processes. The deregulation of cholesterol levels can result in several pathophysiological states. Although studies till date suggest regulatory roles for CHGA and its derived peptides on cholesterol levels, the mechanisms by which this is achieved still remain unclear. This review aims to aggregate and consolidate the available evidence linking CHGA with cholesterol homeostasis in health and disease. In addition, we also look at common molecular regulatory factors (viz., transcription factors and microRNAs) which could govern the expression of CHGA and genes involved in cholesterol homeostasis under basal and pathological conditions. In order to gain further insights into the pathways mediating cholesterol regulation by CHGA/its derived peptides, a few prospective signaling pathways are explored, which could act as primers for future studies. - PublicationFunctional Gly297Ser Variant of the Physiological Dysglycemic Peptide Pancreastatin Is a Novel Risk Factor for Cardiometabolic Disorders(01-03-2022)
;Allu, Prasanna K.R. ;Kiranmayi, Malapaka ;Mukherjee, Sromona D. ;Chirasani, Venkat R. ;Garg, Richa ;Vishnuprabu, Durairajpandian ;Ravi, Sudesh ;Subramanian, Lakshmi ;Sahu, Bhavani S. ;Iyer, Dhanya R. ;Maghajothi, Sakthisree ;Sharma, Saurabh ;Ravi, Marimuthu S. ;Khullar, Madhu ;Munirajan, Arasambattu K. ;Gayen, Jiaur R.; ;Mullasari, Ajit S. ;Mohan, Viswanathan ;Radha, Venkatesan ;Naga Prasad, Sathyamangala V.Pancreastatin (PST), a chromogranin A–derived potent physiological dysglycemic peptide, regulates glucose/insu-lin homeostasis. We have identified a nonsynonymous functional PST variant (p.Gly297Ser; rs9658664) that occurs in a large section of human populations. Association analysis of this single nucleotide polymorphism with cardiovas-cular/metabolic disease states in Indian populations (n 5 ~4,300 subjects) displays elevated plasma glucose, glyco-sylated hemoglobin, diastolic blood pressure, and cate-cholamines in Gly/Ser subjects as compared with wild-type individuals (Gly/Gly). Consistently, the 297Ser allele confers an increased risk (~1.3–1.6-fold) for type 2 diabe-tes/hypertension/coronary artery disease/metabolic syn-drome. In corroboration, the variant peptide (PST-297S) displays gain-of-potency in several cellular events relevant for cardiometabolic disorders (e.g., increased expression of gluconeogenic genes, increased catecholamine secre-tion, and greater inhibition of insulin-stimulated glucose uptake) than the wild-type peptide. Computational docking analysis and molecular dynamics simulations show higher affinity binding of PST-297S peptide with glucose-regu-lated protein 78 (GRP78) and insulin receptor than the wild-type peptide, providing a mechanistic basis for the enhanced activity of the variant peptide. In vitro binding assays validate these in silico predictions of PST peptides binding to GRP78 and insulin receptor. In conclusion, the PST 297Ser allele influences cardiovascular/metabolic phenotypes and emerges as a novel risk factor for type 2 diabetes/hypertension/coronary artery disease in human populations. - PublicationCatestatin is a novel endogenous peptide that regulates cardiac function and blood pressure(01-12-2008)Catestatin is a 21-amino acid residue, cationic and hydrophobic peptide that is formed endogenously by proteolytic cleavage of its precursor chromogranin A, a major protein co-stored and co-released with catecholamines from the storage vesicles in adrenal chromaffin cells and adrenergic neurons. This peptide exhibits potent catecholamine release-inhibitory activity by acting on the neuronal nicotinic acetylcholine receptor. It also stimulates histamine release from mast cells via heterotrimeric G-proteins in a receptor-independent manner. Plasma levels of catestatin are diminished not only in hypertensive patients but also in their still-normotensive offspring, indicating its role in the pathogenesis of hypertension. Consistently, exogenous catestatin rescues hypertension in chromogranin A knockout mice and diminishes blood pressure responses to activation of sympathetic outflow in rats. These hypotensive actions of catestatin may be caused directly by autocrine inhibition of catecholamine release from the sympathoadrenal system and indirectly by paracrine stimulation of the potent vasodilator histamine release from mast cells. Recently, three human variants of catestatin displaying differential potencies for inhibition of catecholamine secretion have been identified. One of these variants (Gly364Ser) causes increased baroreceptor sensitivity, increased cardiac parasympathetic activity, and decreased cardiac sympathetic activity, and it seems to alter the risk for hypertension. These cardiovascular effects may have resulted by action of this peptide in the baroreceptor centre of the nucleus tractus solitarius. Thus, accumulating evidence documents the endogenous peptide catestatin as a novel regulator of cardiac function and blood pressure. © The Author 2008.
- PublicationThe trans-golgi proteins SCLIP and SCG10 interact with chromogranin A to regulate neuroendocrine secretion(08-07-2008)
; ;Taupenot, Laurent ;Courel, Maite ;Mahata, Sushil K.O'Connor, Daniel T.Secretion of proteins and peptides from eukaryotic cells takes place by both constitutive and regulated pathways. Regulated secretion may involve interplay of proteins that are currently unknown. Recent studies suggest an important role of chromogranin A (CHGA) in the regulated secretory pathway in neuroendocrine cells, but the mechanism by which CHGA enters the regulated pathway, or even triggers the formation of the pathway, remains unclear. In this study, we used a transcriptome/proteome-wide approach, to discover binding partners for CHGA, by employing a phage display cDNA library method. Several proteins within or adjacent to the secretory pathway were initially detected as binding partners of recombinant human CHGA. We then focused on the trans-Golgi protein SCLIP (STMN3) and its stathmin paralog SCG10 (STMN2) for functional study. Co-immunoprecipitation experiments confirmed the interaction of each of these two proteins with CHGA in vitro. SCLIP and SCG10 were colocalized to the Golgi apparatus of chromaffin cells in vivo and shared localization with CHGA as it transited the Golgi. Downregulation of either SCLIP or SCG10 by synthetic siRNAs virtually abolished chromaffin cell secretion of a transfected CHGA-EAP chimera (expressing CHGA fused to an enzymatic reporter, and trafficked to the regulated pathway). SCLIP siRNA also decreased the level of secretion of endogenous CHGA and SCG2, as well as transfected human growth hormone, while SCG10 siRNA decreased the level of regulated secretion of endogenous CHGB. Moreover, a dominant negative mutant of SCG10 (Cys22,Cys 24→Ala22,Ala24) significantly blocked secretion of the transfected CHGA-EAP chimera. A decrease in the buoyant density of chromaffin granules was observed after downregulation of SCG10 by siRNA, suggesting participation of these stathmins in granule formation or maturation. We conclude that SCLIP and SCG10 interact with CHGA, share partial colocalization in the Golgi apparatus, and may be necessary for typical transmitter storage and release from chromaffin cells. © 2008 American Chemical Society.